ARTICLE | Clinical News
Farletuzumab regulatory update
April 21, 2008 7:00 AM UTC
The EC granted Orphan Drug designation to Eisai's farletuzumab to treat ovarian cancer. The humanized IgG1 antibody against glycoprotein-3 (GP-3) is in Phase II testing in patients with platinum sens...